Vertex says interim ALYFTREK study data show some CF children ages 2-5 regain pancreatic function

• Vertex flagged interim trial data on ALYFTREK showing some cystic fibrosis children ages 2 to 5 regained pancreatic function.
• Results were presented at the North American Cystic Fibrosis Conference, supporting earlier intervention that may reduce long-term treatment burden.
• Some participants stopped pancreatic enzyme replacement therapy during the open-label extension, suggesting organ function recovery in a subset.
• ALYFTREK use in patients under 6 remains investigational, limiting near-term commercial impact despite positive clinical signal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202610091315BIZWIRE_USPR_____20261009_BW590465) on October 09, 2026, and is solely responsible for the information contained therein.